Hui Tao Li

US Patent:

6763353, Jul 13, 2004

Filed:

Oct 31, 2001

Appl. No.:

09/984975

Inventors:

Hui Li - Union City CA
Shelly Xiaolei Qian - Cupertino CA

Assignee:

Vitria Technology, Inc. - Sunnyvale CA

International Classification:

G06F 1730

US Classification:

707 4, 707 2, 707 3, 707 5, 705 1, 705 7, 709310, 718101

Abstract:

A method for monitoring a business process model in which at least one business process object transitions between states. A query having at least one state for the business process object and at least one time-based condition is defined. The query is applied to the business process objects that have changed since a last query application step as a result of execution of the business process model. Events are published when the results of the query are different from previous results of the query. The time based conditions can include conditions compared to actual time and can aggregated values of attributes of plural business process objects and current time.

US Patent:

7060827, Jun 13, 2006

Filed:

Jun 1, 2004

Appl. No.:

10/858343

Inventors:

Rajinder Singh - Belmont CA, US
Ankush Argade - Foster City CA, US
Donald Payan - Hillsborough CA, US
Susan Molineaux - San Mateo CA, US
Sacha J. Holland - San Francisco CA, US
Jeffrey Clough - Redwood City CA, US
Holger Keim - Menlo Park CA, US
Somasekhar Bhamidipati - Foster City CA, US
Catherine Sylvain - Burlingame CA, US
Hui Li - Millbrae CA, US
Alexander B. Rossi - San Francisco CA, US

Assignee:

Rigel Pharmaceuticals, Inc. - South San Francisco CA

International Classification:

C07D 239/02

US Classification:

544323, 544324, 544320

Abstract:

The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.

US Patent:

7122542, Oct 17, 2006

Filed:

Jul 30, 2004

Appl. No.:

10/903870

Inventors:

Rajinder Singh - Belmont CA, US
Ankush Argade - Foster City CA, US
Hui Li - Millbrae CA, US
Somasekhar Bhamidipati - Foster City CA, US
David Carroll - San Francisco CA, US
Catherine Sylvain - Burligame CA, US
Jeffrey Clough - Redwood City CA, US
Holger Keim - Menlo Park CA, US

Assignee:

Rigel Pharmaceuticals, Inc. - South San Francisco CA

International Classification:

A61K 19/02
A61K 31/535
C07D 268/36

US Classification:

5142305, 544105

Abstract:

The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lups erythematosis and/or its associated symptoms and multiple sclerosis and/or its associated symptoms.

US Patent:

7301254, Nov 27, 2007

Filed:

Jul 24, 2006

Appl. No.:

11/491024

Inventors:

Amit Lal - Ithaca NY, US
Rajesh Duggirala - Ithaca NY, US
Hui Li - Santa Clara CA, US

Assignee:

Cornell Research Foundation, Inc. - Ithaca NY

International Classification:

H02N 1/00
H02N 2/18
H01L 41/08

US Classification:

310309, 310339, 376320

Abstract:

An electrical energy generator with improved efficiency has a base on which is mounted an elastically deformable micromechanical element that has a section that is free to be displaced toward the base. An absorber of radioactively emitted particles is formed on the base or the displaceable section of the deformable element and a source is formed on the other of the displaceable section or the base facing the absorber across a small gap. The radioactive source emits charged particles such as electrons, resulting in a buildup of charge on the absorber, drawing the absorber and source together and storing mechanical energy as the deformable element is bent. When the force between the absorber and the source is sufficient to bring the absorber into effective electrical contact with the source, discharge of the charge between the source and absorber allows the deformable element to spring back, releasing the mechanical energy stored in the element. An electrical generator of improved efficiency includes a first energy source comprising a piezoelectric transducer secured to the deformable element to convert the released mechanical energy to electrical energy. A second energy source comprises a betavoltaic cell carried on the deformable element or electron collector cantilever beam to provide a direct current (DC) power output that can be added to the piezo-electric circuit's alternating current (AC) power output, such that there is a continuous power output that can be used to provide power to electronic circuits.

US Patent:

7329671, Feb 12, 2008

Filed:

Jun 8, 2005

Appl. No.:

11/148746

Inventors:

Rajinder Singh - Belmont CA, US
Ankush Argade - Foster City CA, US
Donald Payan - Hillsborough CA, US
Susan Molineaux - San Mateo CA, US
Sacha J. Holland - San Francisco CA, US
Jeffrey Clough - Redwood City CA, US
Holger Keim - Menlo Park CA, US
Somasekhar Bhamidipati - Foster City CA, US
Catherine Sylvain - Burlingame CA, US
Hui Li - Millbrae CA, US
Alexander B. Rossi - San Francisco CA, US

Assignee:

Rigel Pharmaceuticals, Inc. - South San Francisco CA

International Classification:

A01N 43/54
A01K 31/55

US Classification:

514275, 544323

Abstract:

The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.

US Patent:

7329672, Feb 12, 2008

Filed:

Jun 8, 2005

Appl. No.:

11/149105

Inventors:

Rajinder Singh - Belmont CA, US
Ankush Argade - Foster City CA, US
Donald Payan - Hillsborough CA, US
Susan Molineaux - San Mateo CA, US
Sacha J. Holland - San Francisco CA, US
Jeffrey Clough - Redwood City CA, US
Holger Keim - Menlo Park CA, US
Somasekhar Bhamidipati - Foster City CA, US
Catherine Sylvain - Burlingame CA, US
Hui Li - Millbrae CA, US
Alexander B. Rossi - San Francisco CA, US

Assignee:

Rigel Pharmaceuticals, Inc. - South San Francisco CA

International Classification:

A01N 43/54
A01K 31/505

US Classification:

514275, 544323

Abstract:

The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.

US Patent:

7332484, Feb 19, 2008

Filed:

Jun 8, 2005

Appl. No.:

11/149418

Inventors:

Rajinder Singh - Belmont CA, US
Ankush Argade - Foster City CA, US
Donald Payan - Hillsborough CA, US
Susan Molineaux - San Mateo CA, US
Sacha J. Holland - San Francisco CA, US
Jeffrey Clough - Redwood City CA, US
Holger Keim - Menlo Park CA, US
Somasekhar Bhamidipati - Foster City CA, US
Catherine Sylvain - Burlingame CA, US
Hui Li - Millbrae CA, US
Alexander B. Rossi - San Francisco CA, US

Assignee:

Rigel Pharmaceuticals, Inc. - South San Francisco CA

International Classification:

A61K 31/535

US Classification:

5142305, 514275, 514105, 544323, 544324

Abstract:

The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.

US Patent:

7435814, Oct 14, 2008

Filed:

Dec 8, 2005

Appl. No.:

11/299207

Inventors:

Rajinder Singh - Belmont CA, US
Ankush Argade - Foster City CA, US
Donald Payan - Hillsborough CA, US
Susan Molineaux - San Mateo CA, US
Sacha J. Holland - San Francisco CA, US
Jeffrey Clough - Redwood City CA, US
Holger Keim - Menlo Park CA, US
Somasekhar Bhamidipati - Foster City CA, US
Catherine Sylvain - Burlingame CA, US
Hui Li - Millbrae CA, US
Alexander B. Rossi - San Francisco CA, US

Assignee:

Rigel Pharmaceuticals, Inc. - South San Francisco CA

International Classification:

C07D 403/00

US Classification:

544295, 544324, 544105, 544 48

Abstract:

The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.

Address:

600 Epic Way UNIT 316, San Jose, CA 95134

Phone:

(518)5338682

VIN:

1J4NF4GB5BD207525

Make:

JEEP

Model:

PATRIOT

Year:

2011